Tình hình sử dụng thuốc và tương tác thuốc ở bệnh nhân suy tim mạn điều trị nội trú tại Trung tâm Y tế thị xã Vĩnh Châu năm 2023

Chronic heart failure (CHF) represents a significant global health challenge, necessitating complex, long-term therapeutic regimens often involving multiple medications. This polypharmacy, while crucial for managing symptoms and improving patient outcomes, inherently elevates the risk of adverse drug-drug interactions (DDIs). Such interactions can compromise treatment efficacy and patient safety, particularly in vulnerable populations like the elderly or those with comorbidities. Recognizing this critical issue, a comprehensive assessment of drug utilization patterns and the prevalence and characteristics of DDIs is essential for optimizing patient care. This study, conducted at Vinh Chau Town Medical Center, aims to shed light on these aspects among hospitalized CHF patients, providing valuable insights for safer and more effective clinical practice.

Clinical pharmacists, cardiologists, general practitioners, and healthcare policy makers involved in the management of chronic heart failure.

This retrospective cross-sectional descriptive study investigated drug utilization patterns and drug-drug interactions among 356 hospitalized chronic heart failure (CHF) patients at Vinh Chau Town Medical Center in Soc Trang Province during 2023. The research utilized Micromedex and Drug Interaction Facts databases to evaluate potential drug-drug interactions. Key findings revealed that Angiotensin-converting enzyme inhibitors (ACEIs) were the most frequently prescribed drug group, accounting for 33.71% of prescriptions, aligning with current treatment guidelines. Treatment regimens predominantly involved combinations of two drug classes, making up the highest proportion at 32.30%. A significant proportion of patients, 32.44%, experienced clinically significant drug-drug interactions, with 67.67% of these classified as severe and 64.82% involving pharmacodynamic mechanisms. The most common interacting drug pairs identified included spironolactone, digoxin, furosemide, and captopril, with the spironolactone-digoxin combination being the most prevalent at 4.48%. These results underscore the substantial risk of drug interactions in the management of chronic heart failure patients, particularly those undergoing polypharmacy. The study highlights the necessity for diligent monitoring and proactive management of potential interactions to enhance treatment safety and efficacy, offering practical implications for clinical pharmacists and healthcare providers in optimizing medication regimens and preventing adverse drug events in this patient population.